Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung
Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Cancer & Oncology | Carcinoma | Research | Skin Cancer | Squamous Cell Carcinoma | Tarceva